Aventis' Taxotere Gets Breast Cancer Claim With 25.7% Reduction In Relapse Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
A 1,491-patient study shows overall survival was longer with the docetaxel arm over the TAC and FAC regimens. The approval is the second new indication for Taxotere in the last three months.